In this issue:
- Nipocalimab for moderate- to-severe Sjögren’s disease
- Treat-to-target urate-lowering treatment for gout: CV outcomes
- Cost-utility of subcutaneous methotrexate for RA in the UK
- CTS: an under-recognised feature of RA
- On-label treatment persistence of guselkumab vs. subcutaneous IL-17A inhibitors for PsA
- RA and gout: rare combination or overlooked coexistence?
- Vagus nerve-mediated neuroimmune modulation for RA
- Factors associated with rapid spinal radiographic progression in axial SpA
- Prevalence of several rheumatological diseases in Australia
- Tocilizumab monotherapy after ultrashort glucocorticoid administration in GCA
Please login below to download this issue (PDF)